FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Roches Giredestrant Combo Shows Positive Phase 3 Data

Roche reports new favorable data from the Phase 3 evERA Breast Cancer study of its investigational oral therapy giredestrant, used in combination with...

latest-news-card-1
Biologics

Cell, Gene Therapy Monitoring Guide Encouraging: Attorneys

Attorneys at Hyman, Phelps & McNamara say they are encouraged by an FDA draft guidance outlining a roadmap for postapproval monitoring of cell and gen...

Medical Devices

AdvaMed Proposes MAHA Pathway for Devices

The Advanced Medical Technology Association outlines a series of recommendations aimed at strengthening U.S. leadership in medical technology and safe...

latest-news-card-1
Human Drugs

Summits Ivonescimab Outperforms Tislelizumab in Trial

Summit Therapeutics reports that its investigational bispecific antibody ivonescimab, when combined with chemotherapy, significantly reduced the risk ...

latest-news-card-1
Human Drugs

FDA Updates Rybelsus Label for CV Risk Reduction

FDA approves a new indication for Novo Nordisks Rybelsus (oral semaglutide) tablets to reduce the risk of major adverse cardiovascular events in adult...

latest-news-card-1
Human Drugs

Kenvue Urges FDA to Reject Acetaminophen Petition

Kenvue urges FDA to deny a recent citizen petition requesting updates to the pregnancy warning on acetaminophen products.

latest-news-card-1
Human Drugs

FDA Drug Approval Trends Slipping: Financial Analysts

A new report by RBC Capital Markets finds a slowdown in FDA drug approvals, a rise in rejected applications, and an increase in delayed reviews during...

latest-news-card-1
Human Drugs

Celltrions Yuflyma Expanded Approval for Younger Patients

FDA approves expanded indications for Celltrions Yuflyma (adalimumab-aaty) to include treating hidradenitis suppurativa in adolescent patients aged 12...

latest-news-card-1
Human Drugs

9 Vouchers Awarded Under New Priority Review Pilot

FDA names the first nine voucher recipients under the recently launched Commissioners National Priority Voucher pilot review program.

latest-news-card-1
Human Drugs

FDA OKs Iron-Based MRI Contrast Agent

FDA approves Azurity Pharmaceuticals Ferabright (ferumoxytol injection), an iron-based contrast agent for magnetic resonance imaging of the brain in a...